About Thoratec (NASDAQ:THOR)
Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company's products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD). For acute circulatory support, the Company's product lines are CentriMag Acute Circulatory System (CentriMag) and for pediatric patients PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS). HeartMate III, a centrifugal-flow, chronic, left ventricular assist system.
Industry, Sector and Symbol
Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity8.02%
Return on Assets6.71%
Thoratec (NASDAQ:THOR) Frequently Asked Questions
What is Thoratec's stock symbol?
Thoratec trades on the NASDAQ under the ticker symbol "THOR."
How were Thoratec's earnings last quarter?
Thoratec Co. (NASDAQ:THOR) released its quarterly earnings data on Tuesday, August, 4th. The medical instruments supplier reported $0.37 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.28 by $0.09. The medical instruments supplier had revenue of $128.70 million for the quarter, compared to the consensus estimate of $115.48 million. Thoratec had a net margin of 10.29% and a return on equity of 8.02%. The company's revenue was up 9.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 earnings per share. View Thoratec's Earnings History.
Who are some of Thoratec's key competitors?
Some companies that are related to Thoratec include Thermo Fisher Scientific (TMO), Danaher (DHR), Intuitive Surgical (ISRG), Koninklijke Philips (PHG), Boston Scientific (BSX), Illumina (ILMN), Edwards Lifesciences (EW), Cerner (CERN), Agilent Technologies (A), Waters (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), ABIOMED (ABMD), PerkinElmer (PKI), Sirona Dental Systems (SIRO), Bruker (BRKR) and Alere (ALR).
How do I buy Thoratec stock?
Shares of Thoratec can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Thoratec?
Thoratec's mailing address is 6035 Stoneridge Dr, PLEASANTON, CA 94588, United States. The medical instruments supplier can be reached via phone at +1-925-8478600.
MarketBeat Community Rating for Thoratec (THOR)MarketBeat's community ratings are surveys of what our community members think about Thoratec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Thoratec (NASDAQ:THOR) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Thoratec (NASDAQ:THOR) Earnings History and Estimates Chart
Thoratec (NASDAQ THOR) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/4/2015||Q215||$0.28||$0.37||$115.48 million||$128.70 million||View||Listen|
|5/7/2015||Q115||$0.26||$0.38||$111.10 million||$121.31 million||View||Listen|
|2/10/2015||Q414||$0.24||$0.39||$106.90 million||$127.96 million||View||Listen|
|11/5/2014||Q314||$0.22||$0.18||$106.30 million||$105.80 million||View||Listen|
|8/6/2014||Q214||$0.43||$0.43||$128.30 million||$118.10 million||View||Listen|
|5/6/2014||Q114||$0.39||$0.41||$122.56 million||$125.70 million||View||Listen|
|2/4/2014||Q413||$0.41||$0.38||$128.47 million||$128.20 million||View||Listen|
|10/30/2013||Q313||$0.40||$0.49||$121.25 million||$126.40 million||View||Listen|
|7/31/2013||Q2 2013||$0.43||$0.52||$121.51 million||$130.50 million||View||Listen|
|5/2/2013||Q1 2013||$0.46||$0.41||$122.53 million||$117.73 million||View||Listen|
|2/5/2013||Q4 2012||$0.38||$0.38||$119.09 million||$128.50 million||View||Listen|
|11/1/2012||Q312||$0.39||$0.41||$111.80 million||$117.80 million||View||N/A|
Thoratec (NASDAQ:THOR) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Thoratec (NASDAQ:THOR)
No dividend announcements for this company have been tracked by MarketBeat.com
Thoratec (NASDAQ THOR) Insider Trading and Institutional Ownership History
Thoratec (NASDAQ THOR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/26/2015||Neil F Dimick||Director||Sell||8,173||$44.98||$367,621.54|| |
|5/15/2015||Paul A Laviolette||Director||Sell||5,668||$44.70||$253,359.60|| |
|4/10/2015||Neil F Dimick||Director||Sell||4,786||$43.00||$205,798.00|| |
|12/4/2014||J Daniel Cole||Director||Sell||5,000||$31.83||$159,150.00|| |
|5/27/2014||Neil F Dimick||Director||Sell||4,158||$32.15||$133,679.70|| |
|5/15/2014||Paul Laviolette||Director||Sell||6,023||$31.23||$188,098.29|| |
|3/10/2014||Gerhard Burbach||CEO||Sell||22,104||$36.53||$807,459.12|| |
|2/11/2014||Gerhard Burbach||CEO||Sell||20,000||$34.71||$694,200.00|| |
|1/15/2014||Gerhard Burbach||CEO||Sell||9,400||$38.10||$358,140.00|| |
|1/14/2014||Gerhard Burbach||CEO||Sell||30,600||$36.65||$1,121,490.00|| |
|12/10/2013||Gerhard Burbach||CEO||Sell||40,000||$38.15||$1,526,000.00|| |
|11/12/2013||Gerhard Burbach||CEO||Sell||100,000||$41.40||$4,140,000.00|| |
|10/28/2013||Gerhard F Burbach||CEO||Sell||15,000||$40.02||$600,300.00|| |
|10/17/2013||Gerhard F Burbach||CEO||Sell||9,600||$39.00||$374,400.00|| |
|10/14/2013||Gerhard Burbach||CEO||Sell||40,400||$38.17||$1,542,068.00|| |
|10/11/2013||David Aaron Lehman||SVP||Sell||21,889||$38.17||$835,503.13|| |
|5/28/2013||Neil F Dimick||Director||Sell||1,273||$31.58||$40,201.34|| |
|5/20/2013||Neil F Dimick||Director||Sell||1,250||$31.61||$39,512.50|| |
|5/13/2013||Neil F Dimick||Director||Sell||1,250||$33.93||$42,412.50|| |
|11/26/2012||Gerhard F Burbach||CEO||Sell||11,600||$38.09||$441,844.00|| |
|10/4/2012||David Aaron Lehman||SVP||Sell||12,300||$36.11||$444,153.00|| |
Thoratec (NASDAQ THOR) News Headlines
Thoratec (NASDAQ:THOR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Thoratec (NASDAQ:THOR) Income Statement, Balance Sheet and Cash Flow Statement
Thoratec (NASDAQ THOR) Stock Chart for Tuesday, December, 12, 2017